Press-release for stocks related to pharma for ascendis pharma a/s

Prices are updated after-hours

tags : Pharma entities : Ascendis pharma a::S

save search

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| -7.59% | O: 1.0% H: 0.0% C: -3.9%
pharma conference biopharma global

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
Published: 2024-02-07 (Crawled : 21:00) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 1.15% | O: 1.1% H: 2.19% C: -1.11%
pharma year results

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-07 (Crawled : 13:30) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 0.04% | O: 0.78% H: 0.15% C: -1.87%
pharma conference life sciences

Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
Published: 2024-01-31 (Crawled : 21:00) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 8.44% | O: 0.52% H: 8.58% C: 8.45%
pharma report business year update financial results

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
Published: 2024-01-31 (Crawled : 21:00) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 8.44% | O: 0.52% H: 8.58% C: 8.45%
yorvipath pharma germany

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 6.37% | O: 0.12% H: 2.07% C: 1.34%
pharma company million

Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries
Published: 2024-01-08 (Crawled : 15:30) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 8.61% | O: 0.99% H: 6.15% C: 5.53%
pharma distribution skytrofa yorvipath agreement

Ascendis Pharma Introduces Vision 2030
Published: 2024-01-07 (Crawled : 00:00) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 8.61% | O: 0.99% H: 6.15% C: 5.53%
pharma

Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries
Published: 2024-01-07 (Crawled : 20:20) - prnewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 8.61% | O: 0.99% H: 6.15% C: 5.53%
pharma australia distribution asia therapeutics agreement

Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-28 (Crawled : 21:00) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 10.62% | O: -0.02% H: 0.52% C: -1.09%
pharma conference

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
Published: 2023-11-29 (Crawled : 10:00) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 55.47% | O: 0.64% H: 7.91% C: 6.44%
pharma japan

Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism
Published: 2023-11-20 (Crawled : 13:00) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 48.32% | O: -0.09% H: 2.21% C: -1.2%
yorvipath pharma approval treatment

Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA
Published: 2023-11-15 (Crawled : 13:00) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 48.78% | O: -0.36% H: 1.74% C: -1.47%
fda pharma

Royalty Pharma Reports Third Quarter 2023 Results
Published: 2023-11-08 (Crawled : 12:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -4.61% | O: -0.4% H: 0.32% C: -0.66%
RPRX | $28.17 1.0% 0.99% 1.8M

Health Technology

| 0.22% | O: -1.38% H: 1.77% C: 1.66%
PTCT | $25.32 2.55% 2.49% 3.9M

Health Technology

| 24.19% | O: -0.05% H: 0.0% C: -3.21%
ASND | $140.19 -0.5% -0.5% 270K

Health Technology

| 46.53% | O: -1.78% H: 1.24% C: 0.32%
pharma royalty results

Ascendis Pharma Reports Third Quarter 2023 Financial Results
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K

Health Technology